Skip to main content
Article thumbnail
Location of Repository

Gene expression modulation is associated with gene amplification, supernumerary chromosomes and chromosome loss in antimony-resistant Leishmania infantum

By Philippe Leprohon, Danielle Légaré, Frédéric Raymond, Éric Madore, Gary Hardiman, Jacques Corbeil and Marc Ouellette


Antimonials remain the first line drug against the protozoan parasite Leishmania but their efficacy is threatened by resistance. We carried out a RNA expression profiling analysis comparing an antimony-sensitive and -resistant (Sb2000.1) strain of Leishmania infantum using whole-genome 70-mer oligonucleotide microarrays. Several genes were differentially expressed between the two strains, several of which were found to be physically linked in the genome. MRPA, an ATP-binding cassette (ABC) gene known to be involved in antimony resistance, was overexpressed in the antimony-resistant mutant along with three other tandemly linked genes on chromosome 23. This four gene locus was flanked by 1.4 kb repeated sequences from which an extrachromosomal circular amplicon was generated in the resistant cells. Interestingly, gene expression modulation of entire chromosomes occurred in the antimony-resistant mutant. Southern blots analyses and comparative genomic hybridizations revealed that this was either due to the presence of supernumerary chromosomes or to the loss of one chromosome. Leishmania parasites with haploid chromosomes were viable. Changes in copy number for some of these chromosomes were confirmed in another antimony-resistant strain. Selection of a partial revertant line correlated antimomy resistance levels and the copy number of aneuploid chromosomes, suggesting a putative link between aneuploidy and drug resistance in Leishmania

Topics: Molecular Biology
Publisher: Oxford University Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1992). A novel antifolate resistance gene on the amplified H circle of Leishmania.
  2. (2008). A protein of the leucine-rich repeats (LRRs) superfamily is implicated in antimony resistance in Leishmania infantum amastigotes.
  3. (2007). A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating druginduced programmed cell death.
  4. (2001). A telomere-mediated chromosome fragmentation approach to assess mitotic stability and ploidy alterations of Leishmania chromosomes.
  5. (2005). Advances in leishmaniasis.
  6. (2007). Analysis of the Leishmania donovani transcriptome reveals an ordered 1398
  7. (2006). Aneuploidy and isochromosome formation in drug-resistant Candida albicans.
  8. (2008). Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.
  9. (2007). Caenorhabditis elegans expresses a functional ArsA.
  10. (2007). Characterization of natural antimony resistance in Leishmania donovani isolates.
  11. (1993). Cloning and functional analysis of an extrachromosomally amplified multidrug resistance-like gene in Leishmania enriettii.
  12. (1997). Co-amplification of the gammaglutamylcysteine synthetase gene gsh1 and of the ABC transporter gene pgpA in arsenite-resistant Leishmania tarentolae.
  13. (2007). Comparative genomic analysis of three Leishmania species that cause diverse human disease.
  14. (1994). Contribution of the Leishmania P-glycoprotein-related gene ltpgpA to oxyanion resistance.
  15. (2003). Current treatment approaches to leishmaniasis.
  16. (2007). Differential gene expression analysis in antimonyunresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray.
  17. (1991). Direct and inverted DNA repeats associated with P-glycoprotein gene amplification in drug resistant Leishmania.
  18. (2005). Distinct 30-untranslated region elements regulate stage-specific mRNA accumulation and translation in Leishmania.
  19. (2006). Drug resistance in leishmaniasis.
  20. (2004). Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin.
  21. (2004). Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.
  22. (1997). Efflux systems and increased trypanothione levels in arsenite-resistant Leishmania.
  23. (1999). Elevated levels of polyamines and trypanothione resulting from overexpression of the ornithine decarboxylase gene in arsenite-resistant Leishmania.
  24. (1999). Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimonyresistant strains of Leishmania donovani.
  25. (2007). Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy.
  26. (2006). Expression profiling by whole-genome interspecies microarray hybridization reveals differential gene expression in procyclic promastigotes, lesion-derived amastigotes, and axenic amastigotes in Leishmania mexicana.
  27. (1996). Formation of extrachromosomal circular amplicons with direct or inverted duplications in drug-resistant Leishmania tarentolae.
  28. (2003). Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance.
  29. (1991). Gene amplification in Leishmania.
  30. (2005). Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal.
  31. (2008). Genome-wide gene expression profiling analysis of Leishmania major and Leishmania infantum developmental stages reveals substantial differences between the two species.
  32. (2007). Genomic and proteomic expression analysis of Leishmania promastigote and amastigote life stages: the Leishmania genome is constitutively expressed.
  33. (2007). Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates.
  34. (1993). Homologous recombination between direct repeat sequences yields P-glycoprotein containing amplicons in arsenite resistant Leishmania.
  35. (2008). Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII.
  36. (2007). Increased levels of thiols protect antimony unresponsive Leishmania donovani field isolates against reactive oxygen species generated by trivalent antimony.
  37. (2003). Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs.
  38. (2004). Leishmaniasis: drugs in the clinic, resistance and new developments.
  39. (2002). Life without transcriptional control? From fly to man and back again.
  40. (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments.
  41. (2007). Members of a large retroposon family are determinants of posttranscriptional gene expression in Leishmania.
  42. (1992). Metabolism and functions of trypanothione in the Kinetoplastida.
  43. (2003). Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites.
  44. (2005). Modulation in aquaglyceroporin AQP1 gene transcript levels in drug-resistant Leishmania.
  45. (2008). Modulation of gene expression in drug resistant Leishmania is associated with gene amplification, gene deletion and chromosome aneuploidy.
  46. (2003). Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays.
  47. (2006). Modulation of Leishmania ABC protein gene expression through life stages and among drug-resistant parasites.
  48. (1989). Molecular Cloning.
  49. (2005). Multidrug resistance-associated protein (MRP1) is overexpressed in DNA aneuploid carcinomatous cells in non-small cell lung cancer (NSCLC).
  50. (2003). Normalization of cDNA microarray data.
  51. (2001). Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.
  52. (2003). Novel mechanism of drug resistance in kala azar field isolates.
  53. (1993). Plasticity in chromosome number and testing of essential genes in Leishmania by targeting.
  54. (2005). Ploidy changes associated with disruption of two adjacent genes on Leishmania major chromosome 1.
  55. (1998). Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar,
  56. (2006). Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.
  57. (2005). Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
  58. (2007). Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani.
  59. (2005). Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes.
  60. (2008). Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials.
  61. (1997). Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts.
  62. (1992). The 63-kilobase circular amplicon of tunicamycin-resistant Leishmania amazonensis contains a functional N-acetylglucosamine-1-phosphate transferase gene that can be used as a dominant selectable marker in transfection.
  63. (2005). The genome of the kinetoplastid parasite, Leishmania major.
  64. (2004). The heat shock protein HSP70 and heat shock cognate protein HSC70 contribute to antimony tolerance in the protozoan parasite leishmania.
  65. (2005). Treatment of visceral leishmaniasis.
  66. (1996). Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania.
  67. (2006). Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites.
  68. (2005). Use of within-array replicate spots for assessing differential expression in microarray experiments.
  69. (2000). Widespread aneuploidy revealed by DNA microarray expression profiling.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.